Opus Genetics (IRD)
NASDAQ:IRD
Top Page
Opus Genetics
(NASDAQ:IRD)
Select Model
Select Model
Rating:54Neutral
Price Target:
$4.50
▼(-2.39% Downside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weak financial performance (declining revenue, large losses, and accelerating cash burn). This is partially offset by strong technical positioning (price above key moving averages with positive MACD) and supportive corporate developments, including recent financing and pipeline milestone progress. Valuation is a secondary drag given negative earnings and no dividend support.
Positive Factors
Low Leverage / Conservative Balance Sheet
Minimal debt materially reduces near‑term financial distress risk for a R&D‑heavy biotech. Low leverage preserves flexibility to raise capital on favorable terms, supports continued clinical investment, and limits interest burden, improving chances to reach clinical inflection points without fixed financing costs.
Negative Factors
High Cash Burn / Negative Cash Flow
Sustained negative operating and free cash flow at this magnitude creates an ongoing need for external funding. Persistent burn increases execution risk, can force dilutive financings or unfavorable partnerships, and constrains the company’s ability to autonomously complete multiple clinical programs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Conservative Balance Sheet
Minimal debt materially reduces near‑term financial distress risk for a R&D‑heavy biotech. Low leverage preserves flexibility to raise capital on favorable terms, supports continued clinical investment, and limits interest burden, improving chances to reach clinical inflection points without fixed financing costs.
Read all positive factors
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$328.00M
Dividend YieldN/A
Average Volume (3M)924.82K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth74.60%
EPS Growth-58.14%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding71,149,050
10 Day Avg. Volume494,539
30 Day Avg. Volume924,819
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue19.93
Enterprise Value/Gross Profit34.72
Enterprise Value/Ebitda-6.36
Forecast
1Y Price Target
$10.38Price Target Upside125.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$15.38M
Opus Genetics Business Overview & Revenue Model
Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine...
How the Company Makes Money
null...
Opus Genetics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 14.14M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -38.60M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | |||||
| Total Assets | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | |||||
| Free Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Positive
4.61
Price Trends
3.85
Positive
2.96
Positive
2.19
Positive
Market Momentum
0.16
Positive
54.02
Neutral
53.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Positive. The current price of 4.61 is below the 20-day moving average (MA) of 4.69, above the 50-day MA of 3.85, and above the 200-day MA of 2.19, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 54.02 is Neutral, neither overbought nor oversold. The STOCH value of 53.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRD.
Opus Genetics Risk Analysis
Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opus Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $303.31M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
54 Neutral | $328.00M | -25.22 | -452.26% | ― | 74.60% | -58.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $109.17M | 4.86 | -209.00% | ― | ― | 40.22% | |
50 Neutral | $485.21M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
47 Neutral | $314.74M | -0.23 | ― | ― | -63.96% | -28.50% | |
44 Neutral | $236.34M | -4.18 | -46.90% | ― | -100.00% | 79.01% |
* Healthcare Sector Average
IRD
Opus Genetics
4.61
3.76
444.92%
OVID
Ovid Therapeutics
2.30
2.01
701.39%
STTK
Shattuck Labs
6.78
5.48
421.54%
IKT
Inhibikase Therapeutics
1.79
0.11
6.55%
SRZN
Surrozen
27.40
17.60
179.59%
BMEA
Biomea Fusion
1.51
-0.49
-24.50%
Opus Genetics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Opus Genetics Adopts Change-in-Control Executive Bonus Agreements
Positive
Apr 7, 2026
On April 1, 2026, Opus Genetics, Inc. approved Change in Control Bonus Payment Agreements for its chief executive, financial, operating, and scientific and development officers. The agreements provide that the company will reimburse these executiv...
Business Operations and StrategyPrivate Placements and Financing
Opus Genetics Secures Major Non-Dilutive Funding Facility
Positive
Apr 7, 2026
On April 2, 2026, Opus Genetics entered into a senior secured note purchase agreement providing access to up to $155 million in non-dilutive funding from Oberland Capital, with $105 million committed and an initial $35 million tranche expected to ...
Private Placements and FinancingRegulatory Filings and Compliance
Opus Genetics Closes $25 Million Series B Financing
Positive
Feb 19, 2026
On February 13, 2026, Opus Genetics, Inc. entered into a securities purchase agreement with certain investors for a private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, which closed on February 18, 2026, raisin...
Business Operations and Strategy
Opus Genetics Highlights Gene Therapy Strategy at JPM Conference
Positive
Jan 12, 2026
Opus Genetics, a gene therapy developer targeting rare inherited retinal diseases with a diversified AAV-based pipeline spanning seven indications and two clinical-stage programs, is positioning itself as a focused player in the IRD space with a p...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Opus Genetics Details 2025 Progress and 2026 Milestones
Positive
Jan 8, 2026
On January 8, 2026, Opus Genetics highlighted its 2025 operational progress and outlined key milestones expected in 2026, underscoring the maturation of its multi-asset ophthalmic pipeline and strengthening financial position. In 2025, the company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.